E-LIB Suche - Ergebnisse für: Mehta‐Shah, N.

1

LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF):..:

Kim, Y. H. ; Bagot, M. ; Ortiz‐Romero, P. L....
Hematological Oncology. 41 (2023) S2 - p. 196-197 , 2023

Link: https://doi.org/10.1002/..

2

Duvelisib in patients with relapsed/refractory peripheral T..:

Mehta‐Shah, N. ; Jacobsen, E. D. ; Zinzani, P. L....
Hematological Oncology. 41 (2023) S2 - p. 499-500 , 2023

Link: https://doi.org/10.1002/..

3

Venetoclax combined with R‐ICE (VICER) for second line trea..:

Caimi, P. F. ; Cashen, A. ; Gallogly, M....
Hematological Oncology. 41 (2023) S2 - p. 436-437 , 2023

Link: https://doi.org/10.1002/..

4

GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL..:

Kim, W. ; Cai, Q. ; Song, Y....
Hematological Oncology. 41 (2023) S2 - p. 79-80 , 2023

Link: https://doi.org/10.1002/..

5

Patient‐ versus clinician‐reported symptoms in the POLARIX ..:

Thompson, C. A. ; Mehta‐Shah, N. ; Flowers, C....
Hematological Oncology. 41 (2023) S2 - p. 414-416 , 2023

Link: https://doi.org/10.1002/..

6

THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ..:

Horwitz, S. M. ; Moskowitz, A. J. ; Mehta‐Shah, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

7

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY ..:

Zinzani, P. L. ; Santoro, A. ; Gritti, G....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

Clinical severity measures and quality‐of‐life burden in pa..:

Herbosa, C.M. ; Semenov, Y.R. ; Rosenberg, A.R...
Journal of the European Academy of Dermatology and Venereology. 34 (2020) 5 - p. 995-1003 , 2020

Link: https://doi.org/10.1111/..

9

Current measures are not sufficient: an interview‐based qua..:

Bhat, T.S. ; Herbosa, C.M. ; Rosenberg, A.R....
British Journal of Dermatology. 184 (2020) 2 - p. 310-318 , 2020

Link: https://doi.org/10.1111/..

10

NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/RE..:

Zinzani, P.L. ; Santoro, A. ; Gritti, G....
Hematological Oncology. 37 (2019) S2 - p. 157-158 , 2019

Link: https://doi.org/10.1002/..

11

Health‐related quality of life and economic implications of..:

Semenov, Y.R. ; Rosenberg, A.R. ; Herbosa, C...
British Journal of Dermatology. , 2019

Link: https://doi.org/10.1111/..

12

MULTI‐CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC‐486) PL..:

Ruan, J. ; Leonard, J.P. ; Coleman, M....
Hematological Oncology. 37 (2019) S2 - p. 560-561 , 2019

Link: https://doi.org/10.1002/..

13

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and sa..:

Horwitz, S.M. ; Foss, F.M. ; Porcu, P....
Hematological Oncology. 37 (2019) S2 - p. 65-66 , 2019

Link: https://doi.org/10.1002/..

14

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THER..:

Lunning, M. ; Horwitz, S. ; Advani, R....
Hematological Oncology. 37 (2019) S2 - p. 280-281 , 2019

Link: https://doi.org/10.1002/..

15

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THER..:

Lunning, M. ; Horwitz, S. ; Mehta‐Shah, N....
Hematological Oncology. 35 (2017) S2 - p. 411-412 , 2017

Link: https://doi.org/10.1002/..